Giovanni Caforio, chairman and CEO of Bristol-Myers Squibb Co. (BMS), cut to the chase in unpacking the New York-based pharma's proposed acquisition of the granddaddy of biotech, Celgene Corp., calling the match "a historic day" for both companies with "many compelling benefits."